Eterna Therapeutics Inc
$ 0.27
-11.41%
23 Feb - close price
- Market Cap 7,321,100 USD
- Current Price $ 0.27
- High / Low $ 0.31 / 0.27
- Stock P/E N/A
- Book Value 0.46
- EPS 56.32
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.89 %
- ROE -22.64 %
- 52 Week High 4.95
- 52 Week Low 0.27
About
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Analyst Target Price
$3.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-12 | 2023-11-13 | 2023-08-11 | 2023-05-11 | 2023-03-20 | 2022-11-14 | 2022-08-11 | 2022-04-15 | 2021-12-31 |
| Reported EPS | -0.15 | -0.61 | -2.31 | -0.15 | -1.0335 | -0.8516 | -1.24 | -1.24 | -2.49 | -1.2 | -3.2 | -3.2 |
| Estimated EPS | 0 | 0 | 0 | 0 | None | None | -0.14 | -0.14 | -2.2 | -2.6 | -2.5 | -37.5 |
| Surprise | -0.15 | -0.61 | -2.31 | -0.15 | 0 | 0 | -1.1 | -1.1 | -0.29 | 1.4 | -0.7 | 34.3 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -785.7143% | -785.7143% | -13.1818% | 53.8462% | -28% | 91.4667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ERNA
2026-02-20 14:02:08
Ernexa Therapeutics announced that its President & CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on February 25, 2026, at 4:00 PM ET. Luther will provide a corporate overview and business outlook, followed by a live Q&A session for investors. The company focuses on developing novel cell therapies for advanced cancer and autoimmune diseases, leveraging induced pluripotent stem cells (iPSCs) for scalable, off-the-shelf treatments.
2026-02-20 09:05:00
Ernexa Therapeutics (Nasdaq: ERNA) announced that its President and CEO, Sanjeev Luther, will participate in the Virtual Investor Closing Bell Series on February 25, 2026, at 4:00 PM ET. Luther will provide a corporate overview and business outlook, with investors able to submit live questions. Ernexa Therapeutics specializes in developing novel cell therapies for advanced cancer and autoimmune diseases using engineered induced pluripotent stem cells.
2026-02-18 02:57:30
Charles Cherington, a ten percent owner of Ernexa Therapeutics Inc. (NASDAQ: ERNA), purchased 4,000,000 shares of common stock for $2,000,000 at $0.50 per share, a premium to the current stock price. He also acquired 4,000,000 warrants. This transaction is part of Ernexa's recent $10.5 million public offering and occurs amidst new developments, including participation in the Japan Entry Acceleration Program and regulatory alignment with the FDA.
2026-02-12 02:02:52
Ernexa Therapeutics (ERNA) has secured approximately $10.5 million in gross proceeds through a public offering of common stock, pre-funded warrants, and common warrants. The company entered into a placement agency agreement with Brookline Capital Markets, securities purchase agreements with investors, and a warrant agent agreement with Computershare. These funds will support development programs, working capital, and general corporate purposes.
2026-02-07 12:59:05
Ernexa Therapeutics Inc. announced the pricing of a best-efforts registered public offering totaling $10.5 million. The offering includes 21,000,000 shares of common stock (or equivalents) and warrants to purchase an equal number of shares, priced at $0.50 per share and accompanying warrant. The net proceeds will fund development programs, working capital, and general corporate purposes, with potential additional gross proceeds of $14.3 million if warrants are fully exercised.
2026-02-06 15:59:07
Ernexa Therapeutics Inc. has priced a public offering of 21 million shares and accompanying warrants at $0.50 per share, aiming to raise $10.5 million in gross proceeds. The offering includes warrants exercisable at $0.68 per share, which could bring an additional $14.3 million if fully exercised. The net proceeds are intended for development programs, working capital, and general corporate purposes, crucial for advancing its cell therapy platform for cancer and autoimmune diseases.
